Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.

Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.

For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.

Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.

For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Denarius Metals Offers To Acquire Emerita At Just $0.30 A Share

First Majestic Tracking Ahead Of Guidance Following Q1 Production Results

Related News

Tilray: Haywood Reiterates Hold Rating, $16.50 Price Target

With the Aphria, Tilray (NASDAQ: TLRY) merger finalized and Aphria shares consolidated earlier this month,...

Wednesday, May 19, 2021, 03:38:00 PM

Valens: Canaccord Cuts Price Target To $4.00 Due To Tapered Growth

On July 13, The Valens Company Inc. (TSX: VLNS) reported its second quarter financial results...

Tuesday, July 19, 2022, 04:56:00 PM

Ayr Wellness: Fourth Quarter Consensus Estimates

Ayr Wellness (CSE: AYR.a) is set to report their fourth quarter and year end financials...

Wednesday, March 10, 2021, 11:51:00 AM

Eguana Tech: Stifel Reiterates Buy Rating Following Hawaii VPP Announcement

Last week, Eguana Technologies (TSXV: EGT) announced that they received their first order worth $3.6...

Sunday, July 11, 2021, 10:04:00 AM

Micron Tech: BMO Drops Price Target To $105

Micron Technology (NASDAQ: MU) has had 4 analysts cut their 12-month price targets recently, prior...

Sunday, October 3, 2021, 03:04:00 PM